HEPA

$0.14-6.67%visit website

Hepion Pharmaceuticals, Inc.

Market Cap

$10M

Finnhub, as of 2026-10-17

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

1.69

60mo monthly vs SPY

P/E (TTM)

—

Price / TTM diluted EPS

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

—

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	0	0	70	51	121
Total operating expenses	528	610	799	1,211	3,148
Operating income	(528)	(610)	(799)	(1,211)	(3,148)
Pretax income	(473)	(657)
Net income	(473)	(657)	(811)	(1,248)	(3,188)
EPS (basic) ($)	(0.04)		(0.07)	(0.08)	—
EPS (diluted) ($)	(0.04)		(0.07)	(0.08)	—
Weighted avg. shares (basic)	11,620		11,620	16,193
Weighted avg. shares (diluted)	11,620		11,620	16,193

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 13, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 48 more quarters, back to Q1 FY2014, with Tormere Pro.

Signals

purchases / sales, 90d

Short Volume

—

of daily vol

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Velocity Score

0.13x

Avg Daily Buying (90d)

2,222 sh/day

Baseline Daily Buying

40,816 sh/day

Unique Buyers (90d)

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-09-29	2026-10-02	Fisher Danina	Director	Purchase	200.0K	$0.05	$10K	200.0K	View
2026-08-03	2026-08-12	LoPriore Vincent S	Director & Executive Chairman	Purchase	10.00M	$0.05	$500K	16.25M	View
2026-08-03	2026-08-12	Appajosyula Sireesh	Director & Chief Operating Officer	Purchase	2.00M	$0.05	$100K	3.25M	View
2026-08-03	2026-08-12	Stetz Gary S.	Director & Interim CEO	Purchase	2.00M	$0.05	$100K	3.25M	View
2026-08-03	2026-08-12	Stetz Gary S. II	Director	Purchase	500.0K	$0.05	$25K	500.0K	View

1–5 of 10

1 / 2

Recent News

Hepion Pharmaceuticals (HEPA) grants director 510,000 stock options exercisable at $0.14.

Stock Titan · 2026-10-27

A director receives 510,000 options with a $0.14 exercise price at Hepion Pharmaceuticals (HEPA).

Stock Titan · 2026-10-27

A 1.53M-option award for Hepion Pharmaceuticals (HEPA) CFO carries a $0.14 exercise price.

Stock Titan · 2026-10-27

Hepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac Arrest

Yahoo · 2026-10-26

Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication

Yahoo · 2026-10-19

Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update

Yahoo · 2026-10-14

Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma

Yahoo Finance · 2026-03-03

HEPA Stock Price and Chart — OTC:HEPA

TradingView · 2025-05-14

Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?

InvestorPlace · 2024-04-22

Hepion Pharmaceuticals, Inc. (HEPA) stock price, news, quote and history

Yahoo Finance UK · 2020-02-29

Hepion Pharmaceuticals, Inc. (HEPA) Stock Price, News, Quote & History

Yahoo! Finance Canada · 2019-10-19

HEPA: Hepion Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas

Stocktwits · 2019-07-25

Informational purposes only, not investment advice.

Date	Insider	Type	Shares	Value
2026-09-29	Fisher Danina	P	200,000	$10,000
2026-08-03	LoPriore Vincent S	P	2,000,000	$100,000
2026-08-03	Appajosyula Sireesh	P	2,000,000	$100,000
2026-08-03	Stetz Gary S.	P	2,000,000	$100,000
2026-08-03	Stetz Gary S. II	P	500,000	$25,000

HEPA

Financial Statements

Signals

Factor Profile

Recent News

Hepion Pharmaceuticals, Inc. (HEPA)

Reporting Insiders

Factor Profile